CAJ | 학술논문

目的：探讨树突状细胞共培养细胞因子诱导的杀伤细胞（DC－CIK）联合单药化学治疗(简称化疗)，治疗老年晚期非小细胞肺癌（NSCLC）的临床疗效和安全性。方法回顾性分析106例具有完整随访资料的老年晚期非小细胞肺癌患者，通过比较单药化疗组（A组）、DC－CIK联合单药化疗组（B组）、DC－CIK治疗组（C组）、最佳支持治疗组（D组）间的客观缓解率（ORR）、疾病控制率（DCR）、疾病进展时间（TTP）及严重不良事件发生率（SSR），评价其临床疗效和安全性。结果4组患者ORR比较有显著性差异，其中A组、B组及C组均显著高于D组（ P﹤0.05），但3组间未见明显差异（ P﹥0.05）。4组患者DCR有显著性差异，其中B组显著高于其他3组（ P﹤0.05）。4组患者TTP比较差异明显（ P﹤0.05），其中B组较其他3组明显延长（ P﹤0.05）。D组SSR明显低于其余3组，而B组SSR高于C组，但显著低于A组，差异均有统计学意义（ P﹤0.05）。结论 DC－CIK生物免疫疗法联合单药化疗能安全、有效地延长老年晚期非小细胞肺癌患者的疾病进展时间。
목적：탐토수돌상세포공배양세포인자유도적살상세포（DC－CIK）연합단약화학치료(간칭화료)，치료노년만기비소세포폐암（NSCLC）적림상료효화안전성。방법회고성분석106례구유완정수방자료적노년만기비소세포폐암환자，통과비교단약화료조（A조）、DC－CIK연합단약화료조（B조）、DC－CIK치료조（C조）、최가지지치료조（D조）간적객관완해솔（ORR）、질병공제솔（DCR）、질병진전시간（TTP）급엄중불량사건발생솔（SSR），평개기림상료효화안전성。결과4조환자ORR비교유현저성차이，기중A조、B조급C조균현저고우D조（ P﹤0.05），단3조간미견명현차이（ P﹥0.05）。4조환자DCR유현저성차이，기중B조현저고우기타3조（ P﹤0.05）。4조환자TTP비교차이명현（ P﹤0.05），기중B조교기타3조명현연장（ P﹤0.05）。D조SSR명현저우기여3조，이B조SSR고우C조，단현저저우A조，차이균유통계학의의（ P﹤0.05）。결론 DC－CIK생물면역요법연합단약화료능안전、유효지연장노년만기비소세포폐암환자적질병진전시간。
Objective To investigate clinical effects and safety of dendritic cells co-cultured by cytokine induced killer cells (DC-CIK) combined with mono-chemotherapy in treating elder advanced non-small-cell lung cancer(NSCLC). Methods 106 elderly patients with advanced NSCLC and complete follow-up data were performed the retrospective analysis. The objective response rate (ORR),disease control rate(DCR),time-to-progression(TTP) and severe side-event rate(SSR) were compared among the mono-chemotherapy group(group A),mono-chemotherapy plus DC-CIK group(group B),DC-CIK therapy group(group C)and best support therapy group(D). for evaluating their clinical effect and safety. Results ORR had statistically significant difference among the four groups,which in the group A,B and C was significantly higher than that in the group D( P ﹤ 0. 05),but no obvious differences were found among the group A,B and C( P ﹥ 0. 05). DCR had statistically significant difference among 4 groups,in which the total remis-sion rate in the group B was significantly higher than that in the other 3 groups( P ﹤ 0. 05 ). TTP had significant difference among 4 groups with the statistical significance( P ﹤ 0. 05),which in the group B was significantly extended compared with other 3 groups( P ﹤0. 05). SSR in the group B was significantly lower than that in the other 3 group,but SSR in the group B was higher than that in the group C and lower than that in the group A,the differences all showed the statistical significance( P ﹤ 0. 05). Conclusion DC-CIK combined with mono-chemotherapy can safely and effectively prolong TTP of elderly advanced NSCLC.